New drug combo aims to outperform standard immunotherapy in lung cancer
NCT ID NCT07360132
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether a new experimental drug called HB0025, combined with chemotherapy, works better than the standard immunotherapy pembrolizumab plus chemotherapy for people with advanced squamous non-small cell lung cancer. About 480 participants who have not had prior treatment will be randomly assigned to one of the two combinations. The study is double-blind, meaning neither patients nor doctors know who gets which treatment, and will measure how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HB0025 (an experimental immunotherapy drug) combined with paclitaxel and carboplatin chemotherapy
- What this could lead to
- If successful, this could offer a new first-line treatment option for advanced squamous lung cancer, potentially improving progression-free survival compared to current standard therapy.
- What could go wrong
- This is an early-stage Phase 3 trial with no results yet. The experimental drug may not be more effective than pembrolizumab, and could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The East Hospital Affiliated to Tongji University
Shanghai, Shanghai Municipality, 200120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo outperform standard therapy for lung cancer?
- Can a novel drug combo outperform chemo in lung cancer?
- Can a new drug ASP388B take on advanced solid tumors?
- Could a cheaper copy of keytruda work just as well against cancer?
- New lung cancer cocktail aims to outperform current standard therapy
- New cocktail of immune drugs shows promise in lung cancer trial